gullapalli

The therapy is tailored to address hyper-excitability in the brain, a common issue associated with FXS. Credit: meeboonstudio/Shutterstock. UK-based Kaerus Bioscience has received US Food and Drug Administration’s (FDA) rare paediatric drug and orphan drug designations for its orally bioavailable […]

Boehringer is focusing on difficult-to-treat cancers. Credit: Alex_Traksel/Shutterstock. Boehringer Ingelheim has entered a multi-year partnership with Tempus AI to progress its cancer therapy pipeline. The collaboration builds upon previous joint efforts, utilising AI and data to propel research and the

The partnership aims to address the challenges in supply chain, compliance and regulatory affairs during product development. Credit: Quality Stock Arts / Shutterstock. Contract development and manufacturing organisation (CDMO) Recipharm has partnered with product development and regulatory affairs service provider

The platform utilises bacteria that reside on the skin to locally produce therapeutic biologics. Credit: Eligo Bioscience. Biotechnology company Eligo Bioscience has obtained a $5m grant from the French Government to expedite the development and upscaling of its topical gene

Sarepta is set to receive up to $103.5m in milestone payments related to regulatory and commercial achievements. Credit: T Schneider / Shutterstock. The Japanese Ministry of Health, Labour, and Welfare (MHLW) has granted approval to Sarepta Therapeutics’ gene therapy Elevidys

CGD patients often suffer from severe, recurrent bacterial and fungal infections. Credit: sergey kolesnikov / Shutterstock. The US Food and Drug Administration (FDA) has cleared the investigational new drug application (IND) for Ensoma’s lead programme, EN-374, targeting X-linked chronic granulomatous

The oral tablet is tailored to overcome the limitations of variable pharmacokinetics, toxicity, and poor bioavailability. Credit: danilo.alvesd on Unsplash. The European Commission (EC) has granted orphan drug designation to Biodexa Pharmaceuticals’ oral tablet formulation of rapamycin, eRapa for the

AstraZeneca plans to transition its pMDI portfolio to the near-zero GWP propellant by 2030. Credit: Elzbieta Krzysztof / Shutterstock. The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) inhaler for use with a propellant

MHB088C is developed leveraging Minghui’s SuperTopoi ADC platform. Credit: DW2630 / Shutterstock. Minghui Pharmaceutical has announced an exclusive licensing and partnership agreement with Qilu Pharmaceutical for developing, manufacturing, and commercialising MHB088C in Greater China. Under the deal, Qilu will have

LENZ is focused on developing and commercialising the eye drop for improving near vision in presbyopia patients. Credit: Pheelings media / Shutterstock. US-based LENZ Therapeutics has announced an exclusive licensing and commercialisation agreement with Lotus Pharmaceutical of Taiwan for the